Related Experiment Video

Updated: Aug 18, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Adding aspirin to clopidogrel after TIA and ischemic stroke: benefits do not match risks

Graeme J Hankey1, John W Eikelboom

  • 1Stroke Unit, Department of Neurology, Royal Perth Hospital, Perth, Australia. gjhankey@cyllene.uwa.edu.au

Neurology
|April 13, 2005
PubMed

Insights

Antiplatelet therapy, including aspirin and clopidogrel, helps prevent recurrent stroke. While effective for acute coronary syndrome, the aspirin-clopidogrel combination poses higher risks for recent TIA and ischemic stroke patients.

Area of Science:

  • Neurology
  • Cardiology
  • Pharmacology

Background:

  • Antiplatelet therapy is crucial for preventing secondary vascular events after transient ischemic attack (TIA) and ischemic stroke.
  • Several antiplatelet agents are available, including aspirin, clopidogrel, dipyridamole, and their combinations.

Purpose of the Study:

  • To evaluate the efficacy and safety of different antiplatelet therapies in patients with recent TIA and ischemic stroke.
  • To compare the combination of aspirin and clopidogrel with other antiplatelet regimens in this patient population.

Main Methods:

  • Review of clinical trials and evidence regarding antiplatelet agents.
  • Analysis of comparative effectiveness and safety data for aspirin, clopidogrel, dipyridamole, and combination therapies.

Main Results:

  • Aspirin, clopidogrel, dipyridamole, and aspirin-dipyridamole combinations are effective in reducing recurrent vascular events.
  • The combination of aspirin and clopidogrel shows superior efficacy in acute coronary syndrome but increased hazard in recent TIA/ischemic stroke compared to clopidogrel monotherapy.

Conclusions:

  • Antiplatelet therapy is a cornerstone in managing patients with recent TIA and ischemic stroke.
  • Further research is required to define the role and optimal duration of aspirin-clopidogrel combination therapy in specific high-risk subgroups, such as those with large artery atherothromboembolism.

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Transient Ischemic Attack l: Introduction01:26

Transient Ischemic Attack l: Introduction

A transient ischemic attack (TIA) is a brief episode of neurological dysfunction caused by a temporary, focal reduction in cerebral blood flow. Although symptoms resemble those of an ischemic stroke, the interruption in perfusion is short-lived and does not cause permanent infarction. TIAs are clinically important because they often serve as early warning events for future stroke.Mechanisms of Transient Cerebral IschemiaTransient cerebral ischemia may arise through several mechanisms. One...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...